Institut Kanser Negara - National Cancer Institute ( Site 4302)

Putrajaya, Putrajaya 62250

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Renal Cell

Studies at this site

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) — Running, not enrolling